English Español

A Phase 3b Multicenter Extension Trial Evaluating the Efficacy and Safety of UGN-101 (Mitomycin Gel) for Instillation on Ablation of Upper Urinary Tract Urothelial Carcinoma in Recurrent Patients From Trial TC-UT-03


  • Org Study ID: TC-UT-03/E
  • Secondary ID: N/A
  • NTC ID: NCT04006691
  • Sponsor: UroGen Pharma Ltd.


This trial is designed to evaluate the efficacy and safety of UGN-101 administered to the
upper urinary tract (UUT) in patients who were treated in Trial TC-UT-03, found to be a
complete response (CR) at the Primary Disease Evaluation (PDE) 1 Visit and are subsequently
found to have a documented recurrence of low grade (LG) upper tract urothelial carcinoma
(UTUC) at follow up (FU).


This is an open-label, single-arm, Phase 3b multicenter extension trial, designed to evaluate
the efficacy and safety of UGN-101 administered to the UUT in patients who were treated in
Trial TC-UT-03, found to be a CR at the PDE 1 Visit, and are subsequently found to have a
documented recurrence of LG UTUC at FU.

Upon signing of informed consent, the patients will undergo their routine ureteroscopy to
assess durability. A biopsy will be performed at Visit 0, if appropriate, to confirm evidence
of tumor. If a high grade (HG) UTUC is confirmed by biopsy and/or cytology, the patient will
be excluded from the retreatment trial. Eligible patients with confirmed LG non-invasive UTUC
will be treated with 3 to 6 once-weekly instillations of UGN-101 in a retrograde fashion, per
investigator's discretion.

Five weeks (± 1 week) following the last Investigational product (IP) treatment, the patient
will be assessed for efficacy and safety at the PDE 2 Visit. At this visit, the patient will
undergo ureteroscopy and any remaining lesions will be biopsied, and UUT urine wash will be
collected for cytology.

Patients demonstrating CR at the PDE 2 Visit will undergo FU visits at 3, 6, 9, and 12 months
(± 2 weeks) following the PDE 2 Visit.

The trial will be approximately 15 months, per patient: a 3- to 6-week treatment period,
followed by 4 to 6 weeks post-treatment leading up to the PDE 2 Visit, and a 12-month FU post
PDE 2 Visit. This trial will follow the Steering Committee, and a Data Monitoring Committee
(DMC) has been assigned as established for the primary trial TC-UT-03.

  • Overall Status
  • Start Date
    October 1, 2019
  • Phase
    Phase 3
  • Study Type


Primary Outcome 1 - Measure: Complete response (CR) rate

Primary Outcome 1 - Timeframe: An average of 11 weeks


  • Carcinoma
  • Transitional Cell Carcinoma
  • Transitional Cell Cancer of the Renal Pelvis and Ureter


Main Inclusion Criteria:

1. Patients with recurrent LG UTUC who were found to be CR at the PDE 1 Visit (in Trial

2. Biopsy taken from 1 or more tumors located in the UUT shows LG urothelial carcinoma
(up to 2 months before Visit 0). If there are tumors in both the kidney and the
ureter, at least 1 biopsy should be taken from each location.

3. Urine wash cytology sampled from the UUT documenting the absence of HG urothelial

4. Patients must have adequate organ and bone marrow function as determined by routine
laboratory tests.

5. Patient has no active urinary tract infection (UTI) as confirmed by urine culture or

Main Exclusion Criteria:

1. Patient intends to be treated with systemic chemotherapy during the duration of the

2. Patient with urinary obstruction.

3. Inability to deliver the IP to the UUT.

4. Patient has any other medical or mental condition(s) that make(s) their participation
in the trial unadvisable in the opinion of the treating investigator.

5. Patient has a contraindication to mitomycin treatment, or known sensitivity to

Gender: All

Minimum Age: N/A

Maximum Age: 18 Years

Healthy Volunteers: No


Name: Ifat Klein, Phd

Role: Study Director

Affiliation: UroGen Pharma

Overall Contact

Name: Ifat Klein, Phd

Phone: 1-646-768-9533

Email: Madlen.Malinowski@urogen.com


Facility Status Contact
Facility: Urology Center Las Vegas
Las Vegas, Nevada 89144
United States
Status: Recruiting Contact:
Michael Verni, M.D.